Shanghai Yihao Biotechnology Co., Ltd.

Industry news

FDA-APPROVED CAR T CELL THERAPY FOR NON-HODGKIN LYMPHOMA

FDA-APPROVED CAR T CELL THERAPY FOR NON-HODGKIN LYMPHOMA

2018-06-20

To date, the U.S. Food & Drug Administration (FDA) has approved two forms of CAR T cell therapy for patients with non-Hodgkin lymphoma. City of Hope is one of the only institutions in the United State

View details
With FDA Approval for Advanced Lymphoma, Second CAR T-Cell Therapy Moves to the Clinic

With FDA Approval for Advanced Lymphoma, Second CAR T-Cell Therapy Moves to the Clinic

2018-06-20

Just a month after approving the first cancer therapy that uses genetically engineered immune cells collected from patients, the Food and Drug Administration (FDA) has now cleared a second such therap

View details
CAR T-Cell Therapy

CAR T-Cell Therapy

2018-06-20

Join UCLA pediatric oncologist Satiro De Oliveira, MD, for a discussion about CAR T-cell therapy for pediatric patients, including indications, plan of care, side effects, risks and benefits.

View details
CAR T Cell Therapy

CAR T Cell Therapy

2018-06-20

Chimeric antigen receptor (CAR) T cell therapy is an approach that uses your own immune cells to fight cancer and has shown great promise in treating some types of blood cancers.

View details
< 1 > proceed page

Address:：4F, Block 1C, No. 218 Yindu Road, Xuhui District, Shanghai   Contact:：Miss Jiang
Tel： 021-68811399    Mobile：13601846746   Email：service@yihaobio.com

Copyright: Shanghai Yihao Biological Technology Co., Ltd.

Business license
京ICP备10002622号-38

Power By:www.300.cn  SEO

Shanghai Yihao Biotechnology Co., Ltd.

手机二维码

Shanghai Yihao Biotechnology Co., Ltd.

微信二维码